Premium
Oral phosphodiesterase‐5 inhibitors: effect of heme oxygenase inhibition on cGMP signalling in rat cavernous tissue
Author(s) -
Abdel Aziz M. T.,
Mostafa T.,
Atta H.,
Rashed L.,
Marzouk S. A.,
Obaia E. M.,
Sabry D.,
Hassouna A. A.,
ElShehaby A. M.,
Abdel Aziz A.T.
Publication year - 2007
Publication title -
andrologia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.633
H-Index - 59
eISSN - 1439-0272
pISSN - 0303-4569
DOI - 10.1111/j.1439-0272.2007.00765.x
Subject(s) - tadalafil , cyclic guanosine monophosphate , vardenafil , sildenafil , phosphodiesterase , heme oxygenase , cgmp specific phosphodiesterase type 5 , heme , pharmacology , chemistry , phosphodiesterase 3 , phosphodiesterase inhibitor , endocrinology , medicine , enzyme , biochemistry , nitric oxide
Summary This work postulated that heme oxygenase (HO) is partly responsible for controlling phosphodiesterase‐5 inhibitor actions by modulating cyclic guanosine monophosphate (cGMP) cavernous tissue levels. Five hundred and four male Sprague–Dawley rats, divided into five groups, were investigated. Group 1 ( n = 72) included controls, group 2 ( n = 72) received sildenafil citrate (Viagra R ) orally, group 3 ( n = 72) received vardenafil hydrochloride (Levitra R ), group 4 ( n = 72) received tadalafil (Cialis R ). Group 5 ( n = 216), subdivided into three subgroups (A, B and C, 72 each), received the same dose of each drug with the HO inhibitor, Zn protoporphyrin. Eight rats from each group/subgroup were killed at 0.5, 1, 2, 3, 4, 6, 18, 24 and 36 h when cGMP levels in the cavernous tissues were estimated. Cavernous tissue cGMP levels increased significantly in sildenafil, vardenafil and tadalafil‐treated rats compared to the controls with significant decreases after HO inhibition. It is concluded that the effects of these PDE‐5 inhibitors in rat cavernous tissue are partly mediated through HO activity via the cGMP signalling pathway.